Spinosad - Eli Lilly/ParaPRO

Drug Profile

Spinosad - Eli Lilly/ParaPRO

Alternative Names: LY-232105; Natroba; NatrOVA; PP-105; XDE-105

Latest Information Update: 06 Nov 2018

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Eli Lilly
  • Developer ParaPRO
  • Class Antiparasitics; Macrolides
  • Mechanism of Action GABA receptor agonists; Nervous system stimulants; Nicotinic receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Pediculosis
  • Phase III Scabies

Most Recent Events

  • 03 Aug 2018 ParaPRO completes a phase III trial in Scabies (In adolescents, In adults, In children, In the elderly) in USA (NCT02485704)
  • 25 Jun 2018 ParaPRO completes a phase III trial in Scabies (In adolescents, In adults, In children, In the elderly) in USA (NCT02485717)
  • 10 May 2017 ParaPRO initiates enrolment in a phase III trials in Scabies (In children, In adolescents, In adults, In the elderly) in USA (Topical) (NCT02485704)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top